The first half of 2025 has brought major developments in gastroenterology, spanning new drug approvals, trial data, and clinical guidance. Two major FDA approvals expanded the use of IL-23-targeted therapies in Crohn’s disease: mirikizumab (Omvoh) and guselkumab (Tremfya), both showing strong clinical efficacy across trials.
Trending
- Digital self-management programme for pain, fatigue and faecal incontinence in inflammatory bowel disease: cost-effectiveness analysis of the IBD-BOOST randomised controlled trial (BMJ)
- Clinicians Encouraged to ‘See C. diff Differently’ as Diagnostics, Resistance Patterns, and Therapeutic Tools Shift (GI & Endoscopy News)
- AGA, ACG Express Concerns About New American Cancer Society Recommendations (GI & Endoscopy News)
- In vitro development of the Autonomous Colonoscope Robot System (ACRS) for fully automated colonoscope insertion (Nature)
- Zobair Younossi, MD, on Global Consensus Recommendations for MASLD/MASH (HMP Global Learning Network )
- Recommending Blood Tests for CRC Without Guardrails Risks Confusion (MedPage Today)
- Gut Microbiome Could Remain Disrupted For Over a Decade After Polyp Removal (ScienceAlert)
- Why physician is not the same as provider (KevinMD)
